Insulet Corp. (PODD): Price and Financial Metrics
PODD Price/Volume Stats
Current price | $196.64 | 52-week high | $335.91 |
Prev. close | $198.75 | 52-week low | $125.82 |
Day low | $194.89 | Volume | 424,400 |
Day high | $198.53 | Avg. volume | 819,100 |
50-day MA | $201.46 | Dividend yield | N/A |
200-day MA | $221.80 | Market Cap | 13.73B |
PODD Stock Price Chart Interactive Chart >
PODD POWR Grades
- PODD scores best on the Growth dimension, with a Growth rank ahead of 98.31% of US stocks.
- The strongest trend for PODD is in Stability, which has been heading down over the past 26 weeks.
- PODD's current lowest rank is in the Momentum metric (where it is better than 7.41% of US stocks).
PODD Stock Summary
- PODD's current price/earnings ratio is 113.27, which is higher than 94.68% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for PODD is currently 89.9, higher than 96.79% of US stocks with positive operating cash flow.
- In terms of twelve month growth in earnings before interest and taxes, INSULET CORP is reporting a growth rate of 145.83%; that's higher than 92.43% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to INSULET CORP are CLPS, ESMT, NABL, PAY, and MASI.
- PODD's SEC filings can be seen here. And to visit INSULET CORP's official web site, go to www.insulet.com.
PODD Valuation Summary
- PODD's price/earnings ratio is 126.3; this is 333.28% higher than that of the median Healthcare stock.
- PODD's price/sales ratio has moved down 97.6 over the prior 202 months.
Below are key valuation metrics over time for PODD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
PODD | 2023-12-29 | 9.7 | 24.9 | 126.3 | 107.7 |
PODD | 2023-12-28 | 9.8 | 25.2 | 127.7 | 108.9 |
PODD | 2023-12-27 | 9.9 | 25.5 | 128.8 | 109.8 |
PODD | 2023-12-26 | 9.9 | 25.4 | 128.4 | 109.5 |
PODD | 2023-12-22 | 9.7 | 24.8 | 125.8 | 107.3 |
PODD | 2023-12-21 | 9.8 | 25.2 | 127.4 | 108.6 |
PODD Growth Metrics
- The year over year net cashflow from operations growth rate now stands at -188.95%.
- Its 5 year revenue growth rate is now at 100.43%.
- Its 2 year net cashflow from operations growth rate is now at -152.81%.
The table below shows PODD's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 1,305.3 | 119 | 4.6 |
2022-09-30 | 1,243.3 | 42.8 | 16.8 |
2022-06-30 | 1,178.1 | -39.7 | 34.6 |
2022-03-31 | 1,141.9 | -46.7 | 44.6 |
2021-12-31 | 1,098.8 | -68.1 | 16.8 |
2021-09-30 | 1,037.2 | -43.6 | -29.5 |
PODD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PODD has a Quality Grade of C, ranking ahead of 61.86% of graded US stocks.
- PODD's asset turnover comes in at 0.542 -- ranking 84th of 186 Medical Equipment stocks.
- UFPT, NEPH, and NSPR are the stocks whose asset turnover ratios are most correlated with PODD.
The table below shows PODD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.542 | 0.666 | 0.011 |
2021-03-31 | 0.544 | 0.650 | 0.036 |
2020-12-31 | 0.573 | 0.644 | 0.034 |
2020-09-30 | 0.621 | 0.640 | 0.049 |
2020-06-30 | 0.642 | 0.638 | 0.040 |
2020-03-31 | 0.691 | 0.644 | 0.029 |
PODD Price Target
For more insight on analysts targets of PODD, see our PODD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $290.41 | Average Broker Recommendation | 1.6 (Moderate Buy) |
Insulet Corp. (PODD) Company Bio
A medical device company developing and marketing insulin infusion system. (Source:Wiki)
Latest PODD News From Around the Web
Below are the latest news stories about INSULET CORP that investors may wish to consider to help them evaluate PODD as an investment opportunity.
Here's Why You Should Invest in Insulet (PODD) Stock for NowInvestors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position. |
Bull of the Day: Insulet (PODD)A big earnings beat at the perfect time has this stock up over 50% in short order. |
Top Stock Picks for Week of December 25, 2023An Interesting Bet for Trend Investors and a Leading Medical Products Stock for Your Review |
Here's How Much a $1000 Investment in Insulet Made 10 Years Ago Would Be Worth TodayInvesting in certain stocks can pay off in the long run, especially if you hold on for a decade or more. |
3 Medical-Device Stocks Could Click in 2024Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales. |
PODD Price Returns
1-mo | -3.93% |
3-mo | 26.78% |
6-mo | -12.71% |
1-year | -31.74% |
3-year | -29.99% |
5-year | 139.89% |
YTD | -9.37% |
2023 | -26.30% |
2022 | 10.64% |
2021 | 4.08% |
2020 | 49.32% |
2019 | 115.83% |
Continue Researching PODD
Here are a few links from around the web to help you further your research on Insulet Corp's stock as an investment opportunity:Insulet Corp (PODD) Stock Price | Nasdaq
Insulet Corp (PODD) Stock Quote, History and News - Yahoo Finance
Insulet Corp (PODD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...